Fractyl Health (GUTS) EBIT Margin (2023 - 2024)
Fractyl Health's (GUTS) quarterly EBIT Margin came in at 840333.33% in Q4 2024, down 65489048.0% YoY from N/an in Q1 2024, and down 394.44% on a QoQ basis from 169957.14% in Q3 2024.
Fractyl Health (GUTS) EBIT Margin (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has 2 years of EBIT Margin data on file, last reported at 840333.33% in Q4 2024.
- Quarterly EBIT Margin fell 65489048.0% year-over-year to 840333.33% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 100570.97% (down 5820763.0% YoY) and the FY2024 annual result came in at 100570.97%, down 5820763.0% from the prior year.
- EBIT Margin fell to 840333.33% in Q4 2024, from 169957.14% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 16493.06% in Q2 2023 to a low of 840333.33% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Fractyl Health | 124.59 Mn | 124.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -840,333.33% |
| Sep 30, 2024 | -169,957.14% |
| Jun 30, 2024 | -53,453.49% |
| Mar 31, 2024 | -65,278.79% |
| Dec 31, 2023 | -185,442.86% |
| Sep 30, 2023 | -38,536.11% |
| Jun 30, 2023 | -16,493.06% |
| Mar 31, 2023 | -242,140.00% |